Mark W. Kieran, MD, PhD

Associate Professor, Department of Pediatrics, Harvard Medical School

Associate Professor, Pediatrics, Children's Hospital Boston

Director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute

Contact Info

Mark Kieran
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: SW Rm 331
Phone: 617-632-4907
Fax: 617-632-4897
mark_kieran@dfci.harvard.edu

Assistant

Mayra Mollinedo
Pediatric Oncology
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: SW 331
Phone: 617-632-4386
Fax: 617-632-4897
mayra_mollinedo@dfci.harvard.edu

DF/HCC Program Affiliation

Angiogenesis, Invasion and Metastasis
Outcomes Research
Cancer Survivorship
Neuro-Oncology

Research Abstract

The pediatric brain tumor program has focused on three areas: clinical care, outcomes/long-term follow-up, and translational/ clinical trials development. My focus has been on the latter area (also see Drs Susan Chi, Dr Peter Manley and Dr Nathan Robison) and is centered on two major aspects: novel biologic agents (ras, PDGFR, SHH, mTOR, ErbB and EGFR small molecule inhibitors) and anti-angiogenic agents (TNP470, thalidomide, AZD2171, celingitide) for children with brain tumors. Using a lab-based pre-clinical model structure, we have initiated a number of clinical trials in these areas through the Children's Oncology Group (COG), Pediatric Brain Tumor Consortium (PBTC), Department of Defense (DOD) NF1 Consortium and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC).

Publications

View All Publications

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Mark W. Kieran, MD, PhD Associate Professor, Department of Pediatrics, Harvard Medical School Associate Professor, Pediatrics, Children's Hospital Boston Director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute Contact Info Mark Kieran Dana-Farber Cancer Institute 450 Brookline Avenue Boston, MA, 02215 Mailstop: SW Rm 331 Phone: 617-632-4907 Fax: 617-632-4897 mark_kieran@dfci.harvard.edu Assistant Mayra Mollinedo Pediatric Oncology Dana-Farber Cancer Institute 44 Binney Street Boston, MA, 02115 Mailstop: SW 331 Phone: 617-632-4386 Fax: 617-632-4897 mayra_mollinedo@dfci.harvard.edu DF/HCC Program Affiliation Angiogenesis, Invasion and Metastasis Outcomes Research Cancer Survivorship Neuro-Oncology Research Abstract The pediatric brain tumor program has focused on three areas: clinical care, outcomes/long-term follow-up, and translational/ clinical trials development. My focus has been on the latter area (also see Drs Susan Chi, Dr Peter Manley and Dr Nathan Robison) and is centered on two major aspects: novel biologic agents (ras, PDGFR, SHH, mTOR, ErbB and EGFR small molecule inhibitors) and anti-angiogenic agents (TNP470, thalidomide, AZD2171, celingitide) for children with brain tumors. Using a lab-based pre-clinical model structure, we have initiated a number of clinical trials in these areas through the Children's Oncology Group (COG), Pediatric Brain Tumor Consortium (PBTC), Department of Defense (DOD) NF1 Consortium and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC). Publications View All Publications
Site Map Site Feedback Web Privacy Policy